Intra-Cellular Therapies Inc.(ITCI)_个股概要_股票价格_最新资讯_行情走势_历史数据

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ITCI Intra-Cellular Therapies Inc.

盘前交易 05-02 08:13:27 EDT

72.73

+0.92

+1.28%

最高73.68	最低71.61	成交量71.48万
今开71.61	昨收71.81	日振幅2.88%
总市值76.78亿	流通市值74.18亿	总股本1.06亿
成交额5,189万	换手率0.70%	流通股本1.02亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"ITCI","market":"US","secType":"STK","nameCN":"Intra-Cellular Therapies Inc.","latestPrice":72.73,"timestamp":1714593600000,"preClose":71.81,"halted":0,"volume":714820,"delay":0,"floatShares":102000000,"shares":105570855,"eps":-1.456732,"marketStatus":"盘前交易","marketStatusCode":1,"change":0.92,"latestTime":"05-02 08:13:27 EDT","open":71.61,"high":73.68,"low":71.61,"amount":51887961.757,"amplitude":0.028826,"askPrice":85,"askSize":1,"bidPrice":58.54,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.456732,"exchange":"NASDAQ","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1714656600000},"adr":0,"adjPreClose":72.73,"adrRate":0,"postHourTrading":{"tag":"盘后","latestPrice":72.73,"preClose":72.73,"latestTime":"17:31 EDT","volume":11916,"amount":866653.68,"timestamp":1714599106622},"volumeRatio":1.0564777681334225},"requestUrl":"/m/hq/s/ITCI","defaultTab":"news","newsList":[{"id":"2431327866","title":"Intra-Cellular Therapies Inc    预计每股亏损 32 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2431327866","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2431327866?lang=zh_cn&edition=full","pubTime":"2024-04-30 22:29","pubTimestamp":1714487349,"startTime":"0","endTime":"0","summary":"   * Intra-Cellular Therapies Inc     5月7日公布的截至2024年3月31日的财报显示，该公司的季度收入预计将有所增长。* 根据LSEG的数据，13位分析师的平均预期显示，这家总部位于纽约的公司的营收预计将从去年同期的9,531万美元增长48.3%，达到1.41358亿美元。* LSEG分析师对Intra-Cellular Therapies Inc的平均预期是每股亏损32美分。* 华尔街对 Intra-Cellular Therapies Inc 的 12 个月目标价中值为 91.00 美元，高于其 72.30 美元的最新收盘价。4月30日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2428594171","title":"Intra-Cellular Therapies Inc.盘中异动 早盘急速跳水5.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2428594171","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428594171?lang=zh_cn&edition=full","pubTime":"2024-04-18 21:39","pubTimestamp":1713447583,"startTime":"0","endTime":"0","summary":"北京时间2024年04月18日21时39分，Intra-Cellular Therapies Inc.股票出现异动，股价大幅下跌5.25%。Intra-Cellular Therapies Inc.股票所在的制药行业中，整体跌幅为0.33%。Intra-Cellular Therapies Inc.公司简介：Intra-Cellular Therapies Inc是一家开发治疗中枢神经系统疾病新药的生物技术公司。该信息摘要如下：Needham：重申Intra-Cellular Therapies评级，由买入调整至买入评级, 目标价82.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041821394387e81bc8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041821394387e81bc8&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428107596","title":"BUZZ-细胞内治疗公司因发行 5 亿美元股票而下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2428107596","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2428107596?lang=zh_cn&edition=full","pubTime":"2024-04-18 21:07","pubTimestamp":1713445626,"startTime":"0","endTime":"0","summary":"    4月18日 - ** Intra-Cellular Therapies 的    在后续发行定价后，盘前股价下跌 3.6%，报 73.90 美元。** 生物制药公司周三晚些时候宣布，  ~680万股，发行价为73美元，募集资金总额为5亿美元。** 发行价较上一次销售折价 4.8** 该公司的抑郁症药物在后期研究中达到了主要目标 ，ITCI 的股票周二收盘上涨 23%，报 79.84 美元。** ITCI打算将募集资金净额用于该药物的商业化活动** 根据 LSEG 数据，该公司拥有约 9,680 万股流通股，市值约为 75 亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2428531072","title":"一周缓解抑郁！Intra-Cellular Therapies(ITCI.US)小分子疗法3期试验达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2428531072","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2428531072?lang=zh_cn&edition=full","pubTime":"2024-04-17 20:50","pubTimestamp":1713358205,"startTime":"0","endTime":"0","summary":"Intra-Cellular Therapies(ITCI.US)宣布其小分子疗法Caplyta(lumateperone)作为抑郁症(MDD)辅助疗法的3期试验(Study 501)积极顶线结果。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20240417/20240417204930_67355.png?x-oss-process=image/format,jpg/quality,Q_80","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20240417/20240417204930_67355.png?x-oss-process=image/format,jpg/quality,Q_80"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1104155.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2428360590","title":"美国研究综述-3M、J&J、Nuvalent","url":"https://stock-news.laohu8.com/highlight/detail?id=2428360590","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2428360590?lang=zh_cn&edition=full","pubTime":"2024-04-17 15:48","pubTimestamp":1713340130,"startTime":"0","endTime":"0","summary":"    路透社4月17日 - 华尔街证券分析师周三调整了对几家美国上市公司的评级和目标价，其中包括 3M、J&J 和 Nuvalent。要闻              * 3M公司  ：摩根大通将目标价从118美元下调至110美元             * J&J   ：加拿大皇家银行将目标价从181美元下调至175美元             * Nuvalent Inc   ：Jefferies给予买入评级，目标价97美元             * Tractor Supply Co   ：巴克莱将目标价从192美元上调至234美元             * UnitedHealth Group Inc   ：Piper Sandler将目标价从566美元上调至571美元 以下是路透社周三报道的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2427820108","title":"Intra-Cellular Therapies Inc.股价拉升19.98% 市值涨15.03亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2427820108","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427820108?lang=zh_cn&edition=full","pubTime":"2024-04-16 21:32","pubTimestamp":1713274334,"startTime":"0","endTime":"0","summary":"北京时间2024年04月16日21时32分，Intra-Cellular Therapies Inc.股票出现异动，股价快速拉升19.98%。Intra-Cellular Therapies Inc.股票所在的制药行业中，整体跌幅为0.02%。Intra-Cellular Therapies Inc.公司简介：Intra-Cellular Therapies Inc是一家开发治疗中枢神经系统疾病新药的生物技术公司。该信息摘要如下：Needham：重申Intra-Cellular Therapies评级，由买入调整至买入评级, 目标价82.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404162132148b2a9899&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404162132148b2a9899&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427561827","title":"嗡嗡声--美国股票走势-美国医疗保险公司、Palisade 生物公司、Dynatronics 公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2427561827","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2427561827?lang=zh_cn&edition=full","pubTime":"2024-04-16 21:28","pubTimestamp":1713274132,"startTime":"0","endTime":"0","summary":"        *      个股异动的 Eikon 搜索字符串：[STXBZ］        *      The Day Ahead 新闻通讯：          *      The Morning News Call时事通讯：      4月16日 - 华尔街主要股指周二有望高开，在行业巨头联合健康发布乐观业绩后，医疗保险公司领涨，同时投资者继续关注中东冲突。美东时间9:09，道指电子盘  上涨0.59%，报38,216点。标准普尔500指数小型股  上涨0.17%，报5,112.75点；纳斯达克100指数小型股  上涨0.09%，报17,892.5点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2427153829","title":"BUZZ-抑郁症药物达到后期研究的主要目标，Intra-Cellular Therapies 公司业绩大增","url":"https://stock-news.laohu8.com/highlight/detail?id=2427153829","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2427153829?lang=zh_cn&edition=full","pubTime":"2024-04-16 20:33","pubTimestamp":1713270800,"startTime":"0","endTime":"0","summary":"    4月16日 - ** 制药商Intra-Cellular Therapies的股价  盘前上涨20%至78美元** 该公司称其治疗重度抑郁症的实验性药物在一项后期研究中取得了统计学意义** 与安慰剂相比，在六周时间内，在服用抗抑郁药的同时服用该药达到了通过疾病测量量表测量抑郁症状减少的主要目标** 还达到了降低疾病严重程度的主要次要目标。** 公司表示，第二项后期研究的结果预计将于今年第二季度公布 ** 截至收盘，股价累计下跌 9.6","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2414109975","title":"Intra-Celluar Therapies Inc2023财年实现净利润-1.40亿美元，同比增加45.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2414109975","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2414109975?lang=zh_cn&edition=full","pubTime":"2024-02-26 00:20","pubTimestamp":1708878057,"startTime":"0","endTime":"0","summary":"12月31日，Intra-Celluar Therapies Inc公布财报，公告显示公司2023财年净利润为-1.40亿美元，同比增加45.31%；其中营业收入为4.64亿美元，同比增加85.60%，每股基本收益为-1.46美元。从资产负债表来看，Intra-Celluar Therapies Inc总负债1.37亿美元，其中短期债务3.61百万美元，资产负债比为5.32，流动比率为5.39。机构评级：截至2023年12月31日，当前有15家机构对Intra-Celluar Therapies Inc目标价做出预测，其中目标均价为83.11美元，其中最低目标价为65.00美元，最高目标价为101.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022600210487bdd8df&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022600210487bdd8df&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2413793772","title":"Intra-Celluar Therapies Inc盘中异动 大幅下挫5.04%报68.31美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2413793772","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2413793772?lang=zh_cn&edition=full","pubTime":"2024-02-24 00:09","pubTimestamp":1708704570,"startTime":"0","endTime":"0","summary":"北京时间2024年02月24日00时09分，Intra-Celluar Therapies Inc股票出现波动，股价快速跳水5.04%。截至发稿，该股报68.31美元/股，成交量24.576万股，换手率0.25%，振幅4.31%。Intra-Celluar Therapies Inc股票所在的制药行业中，整体跌幅为0.11%。其相关个股中，Optinose Inc、Emergent Biosolutions Inc、Collegium Pharmaceutical Inc涨幅较大，Agile Therapeutics Inc、Petros Pharmaceuticals Inc、苏轩堂较为活跃，换手率分别为18.68%、17.72%、11.01%，振幅较大的相关个股有Clever Leaves Holdings Inc C/Wts 18/12/2025、Emergent Biosolutions Inc、Agile Therapeutics Inc，振幅分别为20.25%、16.07%、15.83%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240224000931861d7f2f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240224000931861d7f2f&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2413680212","title":"Intra-Celluar Therapies Inc盘中异动 急速跳水7.05%报68.12美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2413680212","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2413680212?lang=zh_cn&edition=full","pubTime":"2024-02-22 22:30","pubTimestamp":1708612244,"startTime":"0","endTime":"0","summary":"北京时间2024年02月22日22时30分，Intra-Celluar Therapies Inc股票出现异动，股价急速下挫7.05%。截至发稿，该股报68.12美元/股，成交量1.7112万股，换手率0.02%，振幅3.94%。Intra-Celluar Therapies Inc股票所在的制药行业中，整体跌幅为0.72%。其相关个股中，Agile Therapeutics Inc、Indivior Plc、Lantheus Holdings Inc涨幅较大，Agile Therapeutics Inc、Petros Pharmaceuticals Inc、苏轩堂较为活跃，换手率分别为344.62%、3.97%、2.32%，振幅较大的相关个股有Bausch Health Companies Inc、Cardiol Therapeutics Inc、Scilex Holding Company，振幅分别为4.15%、4.08%、1.98%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022222304587e723f1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022222304587e723f1&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2405945157","title":"美国研究综述-美国水务公司、家得宝、Lowe's","url":"https://stock-news.laohu8.com/highlight/detail?id=2405945157","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2405945157?lang=zh_cn&edition=full","pubTime":"2024-01-22 15:28","pubTimestamp":1705908512,"startTime":"0","endTime":"0","summary":"    路透1月22日 - 华尔街证券分析师周一调整了对几家美国上市公司的评级和目标价，其中包括美国水务公司、家得宝和劳氏公司。要闻              * 美国水务公司  ：摩根大通将目标价从139美元下调至128美元             * Home Depot Inc   ：奥本海默将其评级从 \"跑赢大盘 \"下调至 \"表现良好\"。* Lowe's Companies Inc   ：奥本海默将其评级从 \"跑赢大盘 \"下调至 \"表现良好\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2393490586","title":"Intra-Celluar Therapies Inc盘中异动 股价大涨6.60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2393490586","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2393490586?lang=zh_cn&edition=full","pubTime":"2023-12-22 22:31","pubTimestamp":1703255480,"startTime":"0","endTime":"0","summary":"北京时间2023年12月22日22时31分，Intra-Celluar Therapies Inc股票出现波动，股价快速上涨6.60%。截至发稿，该股报71.09美元/股，成交量3.1749万股，换手率0.03%，振幅0.99%。Intra-Celluar Therapies Inc股票所在的制药行业中，整体涨幅为0.42%。其相关个股中，大自然药业、Mira Pharmaceuticals Inc、Intercure Ltd涨幅较大，Dmk Pharmaceuticals Corp、Biofrontera Inc、Redhill Biopharma Ltd较为活跃，换手率分别为3.54%、1.07%、0.89%，振幅较大的相关个股有大自然药业、Biofrontera Inc、Petros Pharmaceuticals Inc，振幅分别为15.12%、4.33%、4.16%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023122222312187e6149d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023122222312187e6149d&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2391372924","title":"Intra-Celluar Therapies Inc盘中异动 急速上涨5.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2391372924","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2391372924?lang=zh_cn&edition=full","pubTime":"2023-12-13 01:17","pubTimestamp":1702401479,"startTime":"0","endTime":"0","summary":"北京时间2023年12月13日01时17分，Intra-Celluar Therapies Inc股票出现波动，股价急速拉升5.13%。截至发稿，该股报62.96美元/股，成交量41.5715万股，换手率0.43%，振幅6.49%。Intra-Celluar Therapies Inc股票所在的制药行业中，整体涨幅为0.04%。Intra-Celluar Therapies Inc公司简介：Intra-Cellular Therapies Inc是一家开发治疗中枢神经系统疾病新药的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231213011759861c4a44&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231213011759861c4a44&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.intracellulartherapies.com","stockEarnings":[{"period":"1week","weight":-0.0053},{"period":"1month","weight":0.0653},{"period":"3month","weight":0.0666},{"period":"6month","weight":0.3226},{"period":"1year","weight":0.1497},{"period":"ytd","weight":0.0155}],"compareEarnings":[{"period":"1week","weight":-0.01},{"period":"1month","weight":-0.0418},{"period":"3month","weight":0.0228},{"period":"6month","weight":0.1511},{"period":"1year","weight":0.2179},{"period":"ytd","weight":0.0527}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Intra-cellular Therapies, Inc.（内细胞疗法公司）于2001年5月22日在美国特拉华州注册成立，并于2002年6月开始运营。公司的创立旨在开发药物用于神经和精神疾病的治疗。 ITI公司是一家生物制药公司，专注于创新和发展临床的小分子药物，来改善针对中枢神经系统内精神障碍缺医少药的医疗条件。公司主导产品， ITI- 007 ，临床发展为治疗精神分裂症一流药物。目前用于治疗精神分裂症的药物也没有完全解决中枢神经系统疾病的一系列症状。这些现有的药物也被他们强大的副作用限制。 ITI- 007是用来治疗很多症状，包括急性和残余精神分裂症，具有改进后的安全性和耐受性。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.059554},{"month":2,"riseRate":0.636364,"avgChangeRate":0.027576},{"month":3,"riseRate":0.454545,"avgChangeRate":0.016799},{"month":4,"riseRate":0.545455,"avgChangeRate":-0.004935},{"month":5,"riseRate":0.636364,"avgChangeRate":0.073777},{"month":6,"riseRate":0.7,"avgChangeRate":0.062903},{"month":7,"riseRate":0.2,"avgChangeRate":-0.093},{"month":8,"riseRate":0.3,"avgChangeRate":0.031628},{"month":9,"riseRate":0.3,"avgChangeRate":-0.005124},{"month":10,"riseRate":0.4,"avgChangeRate":0.020152},{"month":11,"riseRate":0.5,"avgChangeRate":0.037942},{"month":12,"riseRate":0.7,"avgChangeRate":0.335648}],"exchange":"NASDAQ","name":"Intra-Cellular Therapies Inc.","nameEN":"Intra-Cellular Therapies"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Intra-Cellular Therapies Inc.(ITCI)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Intra-Cellular Therapies Inc.(ITCI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Intra-Cellular Therapies Inc.,ITCI,Intra-Cellular Therapies Inc.股票,Intra-Cellular Therapies Inc.股票老虎,Intra-Cellular Therapies Inc.股票老虎国际,Intra-Cellular Therapies Inc.行情,Intra-Cellular Therapies Inc.股票行情,Intra-Cellular Therapies Inc.股价,Intra-Cellular Therapies Inc.股市,Intra-Cellular Therapies Inc.股票价格,Intra-Cellular Therapies Inc.股票交易,Intra-Cellular Therapies Inc.股票购买,Intra-Cellular Therapies Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Intra-Cellular Therapies Inc.(ITCI)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Intra-Cellular Therapies Inc.(ITCI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}

公司概况